In July 2025, the company revised its sales and profit outlook for the year, reflecting slower-than-expected uptake for Wegovy and Ozempic, due to intensifying competition from arch-rival Eli Lilly LLY and compounded semaglutide alternatives in its largest obesity market, the United States
10.1186/s40168-018-0605-2 8 DolphinC
Japan is expected to grow at a CAGR of 6.4%, driven by an aging population, high awareness of diabetes management options, and the growing adoption of GLP-1 therapies as part of a comprehensive diabetes care approach
Zhu W, Feng PP, He K, Li SW, Gong JP
Quicksilver's dual liposomal and orobuccal absorption mechanism provides highest bioavailability
Yes, our serum is compatible with most other skincare products